Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Por um escritor misterioso
Last updated 10 novembro 2024
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
eBioMedicine, Vol 93, July 2023
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38  antibody with superior complement-dependent cytotoxic activity -  eBioMedicine
IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine

© 2014-2024 faktorgumruk.com. All rights reserved.